Our global research teams are determined to deliver breakthrough treatments that meet the needs of patients affected by retinal diseases worldwide.
At Johnson & Johnson, we are on a mission to restore and preserve vision in patients with blinding retinal diseases by discovering and developing transformational to prevent, treat or cure diseases with critical global unmet needs.
When Johnson & Johnson commits to a new area, we go at it with the full ambition to be a leader, leveraging our resources to make a meaningful impact for patients. The retinal disease space is no exception, and it’s an area ripe for innovation in which we can employ our multiple platforms to deliver the best science and capabilities across Johnson & Johnson to enable breakthrough therapies.
The potential promise of gene therapy
Pioneering gene therapy innovations is a top priority for Johnson & Johnson. Beginning with the eye, we are investigating gene therapies across varied mechanisms of action, building the case for future applications to other parts of the body.
The gene therapies we are exploring are for a variety of rare and more common retinal diseases, including:
- Inherited retinal diseases, like X-linked retinitis pigmentosa (AAV-RPGR)
- Geographic atrophy, a late-stage and severe form of age-related macular degeneration
Gene therapy is a promising modality for replacing mutation-bearing genes and for the production of therapeutic proteins and has the potential to improve health outcomes for patients worldwide.
Science and innovation beyond gene therapy
In addition to gene therapy, our research teams are vigorously investigating a multitude of therapeutic platforms from topical treatment to systemic therapy to intravitreal injections for more common retinal diseases.
Our cutting-edge research and therapies in clinical trials span the vast retina landscape.
And we’re just getting started.